The European Medicines Agency on Thursday confirmed to Sputnik that it's holding talks with the producer of Russia's Sputnik V vaccine.
"We have indeed been contacted by the developer and are discussing with them further engagement with the Agency. If and when the EMA provides guidance to the developer, we will update the list on our website. Timelines for the authorisation of vaccines are difficult to predict", an EMA spokesperson said.
In view of the pandemic, the EMA and other regulatory agencies in Europe are diverting resources to reduce timelines for the evaluation and authorisation of COVID-19 vaccines, the EMA representative added.
The drug previously showed over 95% efficacy, with the latter uplifting results shown 42 days after the first shot. The evaluation was carried out among 18,794 volunteers.
Samples of Sputnik V have already been delivered to India, Hungary, Armenia, Belarus, and other countries for ongoing trials. Russian President Vladimir Putin said earlier this month that dozens of other countries have also expressed a wish to buy Russia's COVID vaccines, including EpiVacCorona, that was registered in October.